PT3810281T - Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1 - Google Patents

Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1

Info

Publication number: PT3810281T
Authority: PT; Portugal
Prior art keywords: antibodies; cd3xmuc16; methods; treating cancer; bispecific
Prior art date: 2018-06-21

Application number

PT197394729T

Other languages

English (en)

Portuguese (pt)

Original Assignee

Regeneron Pharma

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2018-06-21

Filing date

2019-06-20

Publication date

2024-08-02

2019-06-20 Application filed by Regeneron Pharma filed Critical Regeneron Pharma

2024-08-02 Publication of PT3810281T publication Critical patent/PT3810281T/pt

Links

Classifications

- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2809—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against the T-cell receptor (TcR)-CD3 complex
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/30—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells
- C07K16/3076—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties
- C07K16/3092—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants from tumour cells against structure-related tumour-associated moieties against tumour-associated mucins
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/46—Hybrid immunoglobulins
- C07K16/468—Immunoglobulins having two or more different antigen binding sites, e.g. multifunctional antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
- A61K2039/507—Comprising a combination of two or more separate antibodies
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
- C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/75—Agonist effect on antigen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Immunology (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
Medicinal Chemistry (AREA)
General Health & Medical Sciences (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Molecular Biology (AREA)
Genetics & Genomics (AREA)
Biophysics (AREA)
Biochemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Engineering & Computer Science (AREA)
Epidemiology (AREA)
Cell Biology (AREA)
Microbiology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Mycology (AREA)
Bioinformatics & Cheminformatics (AREA)
Endocrinology (AREA)
Biomedical Technology (AREA)
Oncology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)
Medicinal Preparation (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

PT197394729T 2018-06-21 2019-06-20 Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1 PT3810281T (pt)

Applications Claiming Priority (1)

Application Number	Priority Date	Filing Date	Title
US201862688251P	2018-06-21	2018-06-21

Publications (1)

Publication Number	Publication Date
PT3810281T true PT3810281T (pt)	2024-08-02

Family

ID=67254001

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
PT197394729T PT3810281T (pt)	2018-06-21	2019-06-20	Métodos para tratamento de cancro com anticorpos biespecíficos anti-cd3xmuc16 e anticorpos anti-pd-1

Country Status (26)

Country	Link
US (1)	US11254752B2 (pl)
EP (2)	EP4424712A3 (pl)
JP (1)	JP7403480B2 (pl)
KR (1)	KR102870971B1 (pl)
CN (1)	CN112312970B (pl)
AU (1)	AU2019290170B2 (pl)
BR (1)	BR112020025476A2 (pl)
CA (1)	CA3103887A1 (pl)
CL (1)	CL2020003256A1 (pl)
DK (1)	DK3810281T3 (pl)
EA (1)	EA202190088A1 (pl)
ES (1)	ES2984972T3 (pl)
FI (1)	FI3810281T3 (pl)
HU (1)	HUE067985T2 (pl)
IL (1)	IL279251B2 (pl)
MA (2)	MA71708A (pl)
MX (2)	MX2020013905A (pl)
MY (1)	MY202134A (pl)
PH (1)	PH12020552115A1 (pl)
PL (1)	PL3810281T3 (pl)
PT (1)	PT3810281T (pl)
RS (1)	RS65886B1 (pl)
SG (1)	SG11202012137UA (pl)
TW (2)	TW202504917A (pl)
WO (1)	WO2019246356A1 (pl)
ZA (1)	ZA202007599B (pl)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
WO2016161010A2 (en)	2015-03-30	2016-10-06	Regeneron Pharmaceuticals, Inc.	Heavy chain constant regions with reduced binding to fc gamma receptors
AU2016325630B2 (en)	2015-09-23	2022-11-17	Regeneron Pharmaceuticals, Inc.	Optimized anti-CD3 bispecific antibodies and uses thereof
CA3110513A1 (en)	2018-08-31	2020-03-05	Regeneron Pharmaceuticals, Inc.	Dosing strategy that mitigates cytokine release syndrome for cd3/c20 bispecific antibodies
IL300835A (en) *	2020-09-02	2023-04-01	Genmab As	Antibody therapy
AU2022214319A1 (en)	2021-01-28	2023-08-03	Regeneron Pharmaceuticals, Inc.	Compositions and methods for treating cytokine release syndrome
WO2022197907A2 (en) *	2021-03-18	2022-09-22	Memorial Sloan-Kettering Cancer Center	Methods for treating gynecologic cancer using combination therapy with anti-muc16 x cd3 multispecific antibodies and vegf inhibitors
EP4397320A1 (en)	2021-08-31	2024-07-10	Nihon Medi-Physics Co., Ltd.	Radioactive complex of deglycosylated antibody and radioactive pharmaceutical product
EP4437003A1 (en) *	2021-11-24	2024-10-02	Regeneron Pharmaceuticals, Inc.	Methods for treating cancer with bispecific anti-cd3 x muc16 antibodies and anti-ctla-4 antibodies
US20230312718A1 (en) *	2022-01-07	2023-10-05	Regeneron Pharmaceuticals, Inc	Methods of Treating Recurrent Ovarian Cancer with Bispecific Anti-MUC16 x Anti-CD3 Antibodies Alone or in Combination with Anti-PD-1 Antibodies
JP2025504795A (ja)	2022-01-10	2025-02-19	ナンチンリーズバイオラブスカンパニー，リミティド	抗体及びその用途
US20250195645A1 (en) *	2022-03-16	2025-06-19	Daiichi Sankyo Company, Limited	Combination of multispecific molecule and immune checkpoint inhibitor
EP4507790A1 (en)	2022-04-11	2025-02-19	Regeneron Pharmaceuticals, Inc.	Compositions and methods for universal tumor cell killing
CN120857940A (zh)	2023-02-17	2025-10-28	瑞泽恩制药公司	对cd3/taa双特异性抗体有反应的诱导型nk细胞

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7087411B2 (en)	1999-06-08	2006-08-08	Regeneron Pharmaceuticals, Inc.	Fusion protein capable of binding VEGF
PL354286A1 (pl)	1999-08-23	2003-12-29	Dana-Farber Cancer Institutedana-Farber Cancer Institute	Receptor PD-1 dla B7-4 i jego zastosowaniaReceptor PD-1 dla B7-4 i jego zastosowania
CN101899114A (zh)	2002-12-23	2010-12-01	惠氏公司	抗pd-1抗体及其用途
DK2439273T3 (da)	2005-05-09	2019-06-03	Ono Pharmaceutical Co	Humane monoklonale antistoffer til programmeret død-1(pd-1) og fremgangsmåder til behandling af cancer ved anvendelse af anti-pd-1- antistoffer alene eller i kombination med andre immunterapeutika
BR122017025062B8 (pt)	2007-06-18	2021-07-27	Merck Sharp & Dohme	anticorpo monoclonal ou fragmento de anticorpo para o receptor de morte programada humano pd-1, polinucleotídeo e composição compreendendo o referido anticorpo ou fragmento
EP2262837A4 (en)	2008-03-12	2011-04-06	Merck Sharp & Dohme	PD-1 BINDING PROTEINS
AU2009288730B2 (en)	2008-08-25	2013-06-20	Amplimmune, Inc.	Compositions of PD-1 antagonists and methods of use
MY192182A (en)	2009-06-26	2022-08-04	Regeneron Pharma	Readily isolated bispecific antibodies with native immunoglobulin format
CA2840018C (en)	2011-07-24	2019-07-16	Curetech Ltd.	Variants of humanized immunomodulatory monoclonal antibodies
TWI635098B (zh)	2013-02-01	2018-09-11	再生元醫藥公司	含嵌合恆定區之抗體
TWI681969B (zh) *	2014-01-23	2020-01-11	美商再生元醫藥公司	針對ｐｄ-１的人類抗體
TWI701042B (zh)	2014-03-19	2020-08-11	美商再生元醫藥公司	用於腫瘤治療之方法及抗體組成物
AU2016325630B2 (en) *	2015-09-23	2022-11-17	Regeneron Pharmaceuticals, Inc.	Optimized anti-CD3 bispecific antibodies and uses thereof
LT3394103T (lt) *	2015-12-22	2023-09-11	Regeneron Pharmaceuticals, Inc.	Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
TWI910495B (zh)	2016-05-13	2026-01-01	美商再生元醫藥公司	藉由投予pd-1抑制劑治療皮膚癌之方法
JP7066690B2 (ja)	2016-09-23	2022-05-13	リジェネロン・ファーマシューティカルズ・インコーポレイテッド	抗ｍｕｃ１６（ムチン１６）抗体
MY203000A (en) *	2016-10-14	2024-06-01	Xencor Inc	Il15/il15r� heterodimeric fc-fusion proteins
BR112019010878A2 (pt)	2016-11-29	2019-10-01	Lindhofer Horst	combinação de anticorpos multifuncionais de redirecionamento de células t com moduladores de ponto de verificação imunológico e usos dos mesmos

2019
- 2019-06-19 TW TW113114645A patent/TW202504917A/zh unknown
- 2019-06-19 TW TW108121196A patent/TWI890661B/zh active
- 2019-06-20 MA MA71708A patent/MA71708A/fr unknown
- 2019-06-20 ES ES19739472T patent/ES2984972T3/es active Active
- 2019-06-20 EP EP24176671.6A patent/EP4424712A3/en active Pending
- 2019-06-20 SG SG11202012137UA patent/SG11202012137UA/en unknown
- 2019-06-20 US US16/447,067 patent/US11254752B2/en active Active
- 2019-06-20 CA CA3103887A patent/CA3103887A1/en active Pending
- 2019-06-20 KR KR1020217000649A patent/KR102870971B1/ko active Active
- 2019-06-20 BR BR112020025476-2A patent/BR112020025476A2/pt unknown
- 2019-06-20 MA MA52962A patent/MA52962B1/fr unknown
- 2019-06-20 RS RS20240959A patent/RS65886B1/sr unknown
- 2019-06-20 AU AU2019290170A patent/AU2019290170B2/en active Active
- 2019-06-20 MX MX2020013905A patent/MX2020013905A/es unknown
- 2019-06-20 DK DK19739472.9T patent/DK3810281T3/da active
- 2019-06-20 PT PT197394729T patent/PT3810281T/pt unknown
- 2019-06-20 EA EA202190088A patent/EA202190088A1/ru unknown
- 2019-06-20 IL IL279251A patent/IL279251B2/en unknown
- 2019-06-20 JP JP2020570938A patent/JP7403480B2/ja active Active
- 2019-06-20 CN CN201980040564.9A patent/CN112312970B/zh active Active
- 2019-06-20 MY MYPI2020006505A patent/MY202134A/en unknown
- 2019-06-20 PL PL19739472.9T patent/PL3810281T3/pl unknown
- 2019-06-20 WO PCT/US2019/038163 patent/WO2019246356A1/en not_active Ceased
- 2019-06-20 HU HUE19739472A patent/HUE067985T2/hu unknown
- 2019-06-20 EP EP19739472.9A patent/EP3810281B1/en active Active
- 2019-06-20 FI FIEP19739472.9T patent/FI3810281T3/fi active
2020
- 2020-12-07 ZA ZA2020/07599A patent/ZA202007599B/en unknown
- 2020-12-10 PH PH12020552115A patent/PH12020552115A1/en unknown
- 2020-12-16 MX MX2025008444A patent/MX2025008444A/es unknown
- 2020-12-16 CL CL2020003256A patent/CL2020003256A1/es unknown

Also Published As

Publication number	Publication date
MA52962B1 (fr)	2024-10-31
JP2021528423A (ja)	2021-10-21
JP7403480B2 (ja)	2023-12-22
CN112312970B (zh)	2025-05-23
EP4424712A2 (en)	2024-09-04
RS65886B1 (sr)	2024-09-30
EP3810281B1 (en)	2024-07-24
TW202504917A (zh)	2025-02-01
TWI890661B (zh)	2025-07-21
MA71708A (fr)	2025-05-30
WO2019246356A1 (en)	2019-12-26
TW202005985A (zh)	2020-02-01
AU2019290170A1 (en)	2021-01-07
DK3810281T3 (da)	2024-08-19
EP4424712A3 (en)	2024-11-13
CL2020003256A1 (es)	2021-04-30
HUE067985T2 (hu)	2024-12-28
FI3810281T3 (fi)	2024-08-14
CN112312970A (zh)	2021-02-02
MY202134A (en)	2024-04-05
PH12020552115A1 (en)	2021-08-02
CA3103887A1 (en)	2019-12-26
SG11202012137UA (en)	2021-01-28
ES2984972T3 (es)	2024-10-31
MX2025008444A (es)	2025-08-01
MA52962A (fr)	2021-04-28
US11254752B2 (en)	2022-02-22
IL279251B1 (en)	2025-11-01
IL279251A (en)	2021-01-31
BR112020025476A2 (pt)	2021-03-16
IL279251B2 (en)	2026-03-01
PL3810281T3 (pl)	2024-11-04
ZA202007599B (en)	2025-02-26
KR20210023981A (ko)	2021-03-04
AU2019290170B2 (en)	2026-04-02
US20190389966A1 (en)	2019-12-26
MX2020013905A (es)	2021-03-09
KR102870971B1 (ko)	2025-10-16
EP3810281A1 (en)	2021-04-28
EA202190088A1 (ru)	2021-03-22

Publication	Publication Date	Title
IL279251A (en)	2021-01-31	Methods for treating cancer with bispecific antibodies against CD3XMUC16 and antibodies against PD-1
IL276303A (en)	2020-09-30	Methods of treating cancer with ANTI-PD-1 antibodies
IL267804A (en)	2019-09-26	Methods for treating cancer with anti-pd-1 antibodies
IL289946A (en)	2022-03-01	Bispecific antibodies against cd3 and cd20
IL283530A (en)	2021-07-29	Bispecific anti-pd-l1/anti-4-1bb antibodies and their uses
ZA202004735B (en)	2023-06-28	Anti-pd-1 antibodies and methods of treatment
LT3394103T (lt)	2023-09-11	Antikūnų prieš pd-1 ir bispecifinių antikūnų prieš cd20/cd3 derinys, skirtas vėžiui gydyti
ZA202005223B (en)	2022-03-30	Methods of treating cancers with antagonistic anti-pd-1 antibodies
IL267803A (en)	2019-09-26	Methods for treating cancer with anti-tim-3 antibodies
IL275940A (en)	2020-08-31	Combined treatment with antibodies against IL-8 and against PD-1 for cancer treatment
IL248511A0 (en)	2016-12-29	Combined therapy for the treatment of cancer with a focovirus expressing the antigen and a monoclonal antibody against tim-3
SG11201705252UA (en)	2017-07-28	Anti-pd-1 monoclonal antibodies and obtaining method thereof
IL266990A (en)	2019-07-31	Methods for treating cancer using anti-pd-l1 antibodies and antiandrogens
SG10201912545PA (en)	2020-02-27	T cell redirecting bispecific antibodies for the treatment of egfr positive cancers
IL281441B (en)	2022-10-01	Anti-cxcl13 antibodies for the treatment of autoimmune diseases and cancer
IL272669A (en)	2020-03-31	Combination therapy with a combination of anti-CSF1R and anti-PD-1 antibodies for pancreatic cancer
SG11202103589XA (en)	2021-05-28	Materials and methods for treating cancer
ZA202204423B (en)	2023-01-25	Methods of cancer treatment using anti-ox40 antibodies in combination with anti-pd1 or anti-pdl1 antibodies
ZA202204422B (en)	2023-05-31	Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tigit antibodies
ZA202204252B (en)	2023-01-25	Methods of cancer treatment using anti-ox40 antibodies in combination with anti-tim3 antibodies
HK40034729A (en)	2021-04-30	Methods for treating cancer with anti-pd-1 antibodies
HK40079158A (en)	2023-04-14	Methods of treating cancer with anti-pd-1 antibodies
HK40028770A (en)	2021-02-05	Compositions and methods for treating cancer with anti-egfr antibodies
GB201819026D0 (en)	2019-01-09	Means and methods for treating cancer
HK40021222A (en)	2020-10-30	Methods for treating cancer using ps-targeting antibodies with immuno-oncology agents